CD163 and systemic sclerosis: In cultured SSc-ILD MDMs, nintedanib 0.1 and 1μM did not induced any significant decrease in the protein synthesis of CD204, CD206, and CD163 compared to untreated cells after 3 and 16 h of treatment (Fig. 4).